Table 2.
Summary of effects of MB or PBM on neurodegenerative disorders and brain injury
Disease | Effect of a treatment with MB | Effect of a treatment with PBM |
---|---|---|
AD | • Increases functional MRI activity and improves memory retrieval [200] | • Reduces hyperphosphorylated tau, neurofibrillary tangles, and oxidative stress [234, 235] |
• Decreases Aβ levels and Aβ-ABAD binding [226] | • Increases the ability of Aβ phagocytosis [236] | |
• Attenuates the activity and expression of β-secretase, inhibits the formation of neurotoxic oligomeric Aβ, and improves behavioral results [19, 20, 198] | • Improves spatial learning and memory by significantly reducing Aβ burden [236] | |
• Exerts neuroprotection by activating the | ||
• Inhibits p-tau aggregation and tau-tau interactions [229, 230] | ERK/CREB pathway and upregulating the expression of BDNF [237] | |
• Reduces excessive ROS production [17, 22] | ||
• Upregulates Complex IV activates, heme synthesis and mitochondrial function [226, 231–233] | • Restores mitochondrial dynamics [8] | |
TBI | • Decreases edema and lesion volume and improves behavioral scores [163] | • Neurological improvement [246] |
• Increases autophagy [242]. | • Increases mitochondrial function, improves blood flow, and reduces swelling [244, 247] | |
• Inhibits excessive ROS production and attenuates mitochondrial dysfunction, cytochrome c release, and neuronal apoptosis [243] | ||
• Decreases oxidative stress, inhibits inflammation, and attenuates apoptosis [244, 247] | ||
Stroke | • Improves behavioral results after focal cerebral ischemia [16] | • Improves neurological rating scores [4, 255, 256] |
• Decreases lesion volume, cerebral edema, and gray and white- matter damage [16, 18] | • Stimulates neurogenesis and improves mitochondrial function [4, 262] | |
• Increases cerebral global glucose uptake and blood flow [251, 252] | • Preserves mitochondrial integrity [263] | |
• Increases mitochondrial function [9, 252] | • Attenuates mitochondrial fragmentation and restores mitochondrial dynamics [254] | |
• Preserves mitochondrial structure and function [253] | ||
• Increases mitophagy and preserves mitochondrial membrane potential [253] | • Decreases protein carbonylation, DNA oxidative damage, and lipid peroxidation [254] | |
Depression | • Improves the symptoms of patients with severe depression [265] | • Improves depressive symptoms [274–277] |
• Selectively inhibits nitric oxide synthase (NOS) [264, 265, 270, 271] | • Improves ATP production and increases activity and expression of mitochondrial Complex IV [208] | |
PD | • Attenuates dopamine loss and reduces the disruption of mitochondrial function and excessive production of ROS [280–284] | • Reduces cell loss and inhibits inflammatory amoeboid microglia [287–290] |
• Improves Complexes I, II, and III activities, reduces free radical production, and improves behavioral results [252, 285] | • Improves speech, cognition, gait, and freezing episodes in PD patients [291, 292] | |
• Upregulates brain-derived neurotrophic factor (BDNF) expression [286] | • Improves mitochondrial function and reduces oxidative stress [293] |